Home > Insider Trading > Latest 13D and 13G Filings > 13G Filing (0001104659-25-063100)

Filing Details

Accession Number:: 0001104659-25-063100
Form Type:: 13G Filing
Publication Date:: 2025-06-25 20:00:00

Filed By:: Ewon Comfortech Co., Ltd.
Company:: Liminatus Pharma Inc.
Filing Date:: 2025-06-26
SEC Url:: 13G Filing

Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name	Beneficially Owned Number of Shares	Beneficially Owned Number of Aggregate Shares	Percent of Class
Ewon Comfortech Co., Ltd.	0	1,500,000	5.8%

Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Liminatus Pharma, Inc.

(Name of Issuer)

Common Stock , par value $0.0001 per share

(Title of Class of Securities)

53271X108

(CUSIP Number)

04/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

53271X108

Names of Reporting Persons

Ewon Comfortech Co., Ltd.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

KOREA, REPUBLIC OF

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,500,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,500,000.00
8	Shared Dispositive Power 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

1,500,000.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

5.8 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: * Percentage is calculated based on 26,014,633 shares of Common Stock outstanding upon consummation of the Business Combination on April 30, 2025.

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Liminatus Pharma, Inc.

(b)

Address of issuer's principal executive offices:

6 Centerpointe Drive #625, La Palma, CA 90623

Item 2.

(a)

Name of person filing:

Ewon Comfortech Co., Ltd.

(b)

Address or principal business office or, if none, residence:

8 Cheomdan 1-ro Jeongeup, Jeonbuk, 56212 Republic of South Korea

(c)

Citizenship:

Republic of South Korea

(d)

Title of class of securities:

Common Stock , par value $0.0001 per share

(e)

CUSIP No.:

53271X108

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

1,500,000

(b)

Percent of class:

5.8%

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

1,500,000

(ii) Shared power to vote or to direct the vote:

(iii) Sole power to dispose or to direct the disposition of:

1,500,000

(iv) Shared power to dispose or to direct the disposition of:

Item 5.

Ownership of 5 Percent or Less of a Class.

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Ewon Comfortech Co., Ltd.

Signature:	/s/ Joo Sung Park
Name/Title:	Joo Sung Park, Chief Executive Officer
Date:	06/26/2025

Exhibit Information

1. The PIPE Equity Subscription Agreement, dated November 30, 2022, as amended, by and among Iris Acquisition Corp, Iris Parent Holding Corp., and Ewon Comfortech Co., Ltd. (incorporated by reference to Annex E of Form 424B3 filed by the Issuer with the SEC on February 7, 2025). 2. Amended and Restated Registration Rights Agreement, dated as of April 30, 2025, by and among Iris Acquisition Corp, Iris Parent Holding Corp, Iris Acquisition Holdings LLC, Cantor Fitzgerald & Co. and certain other parties thereto (incorporated by reference to Exhibit 10.1 of Form 8-K filed by the Issuer with the SEC on May 6, 2025). 3. Lock-Up Agreement, dated November 30, 2022, by and among Iris Parent Holding Corp., Iris Acquisition Holdings LLC and certain members of Liminatus Pharma, LLC (incorporated by reference to Exhibit 10.2 of Form 8-K filed by the Issuer with the SEC on May 6, 2025).